News
TUESDAY, April 15, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adults with unresectable or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback